Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC

Pachyonychia Congenita Clinical Trial

Official title:

Phase 1b, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of a 1% Topical Formulation of KM-001 for the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenita

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05956314
• Other study ID #: KM001-B1B
• Status: Recruiting
• Phase: Phase 1
• Start date: March 6, 2023
• Est. completion date: August 31, 2024

Study information

• Verified date: April 2024
• Source: Kamari Pharma Ltd
• Contact: Shelly Leibrman-Barak
• Phone: +972-52-6919977
• Email: shelly[@]kamaripharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1b, open-label, single-center, prospective trial will be assessing the safety, tolerability, and efficacy of topical KM-001 1% in patients with PPPK1 or PC diseases. In this study 2 cohorts will be recruited: 1. Cohort 1: up to 11 eligible patients, will be enrolled to be treated twice daily, for 12 weeks, with 1% topical KM-001, on the plantar surfaces (2 feet). 2. Cohort 2: up to 8 eligible patients, will be enrolled to be treated twice daily, for 16 weeks, with 1% topical KM-001, on the plantar surfaces (2 feet). Safety (AEs, blood work [at specific visits], vital signs), tolerability, and efficacy parameters (overall lesion improvement) will be assessed during in-clinic visits (Cohort 1: during Screening, Enrolment, and on Days 7, 28, 42, 63, 84 [end of treatment, EoT], 112 [End of Study, EoS] post first investigational medicinal product (IMP) administration; Cohort 2: during Screening, Enrolment, and on Days 7, 28, 42, 63, 84, 112 [EoT], 140 [EoS] post first investigational medicinal product (IMP) administration). PK samples will be collected to assess plasma levels of KM-001 on - Screening (Day -14 to -0): any time during the visit. (or on Day 1 up to 30 minutes pre-dose if missed during Screening) - Day 7 and at EoT (Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose, and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose - Days 28, 42 for both Cohorts, and Day 84 for Cohort 2: 1 sample after the first dose, before the second dose, as late as possible in the visit. - End of Study (EoS, Day 112 (Cohort 1) or Day 140 (cohort 2)), or at Early Termination (ET): at any time during the visit. The patient will complete a patient-reported diary, consisting of treatment compliance and self-assessments for efficacy. Follow up- 2 weeks after EoT by phone call, and 4 weeks after EoT in clinic visit.

Description:

The palmoplantar keratoderma (PPK) group of skin disorders results from various mutations in several epidermal genes and is characterized by thickening of the skin on the palms and soles. Punctate palmoplantar keratoderma (PPKP1) is a rare autosomal, dominant, inherited skin disease characterized by bilateral asymptomatic, tiny, hyperkeratotic punctate papules and plaques on the palmoplantar surface. Pachyonychia congenita (PC) is a rare group of autosomal dominant skin disorders that are caused by a mutation in one of five different keratin genes. PC is often associated with thickened toenails, plantar keratoderma, and plantar pain. Its manifestations include bilateral PPK on palms and soles pattern with sharp margins and a yellow tone. A common characteristic of these skin diseases is the impaired differentiation of keratinocytes, often caused by defective calcium homeostasis. Normal calcium homeostasis is regulated by calcium ion channels, including the transient receptor potential cation channel subfamily V, member 3 (TRPV3), which has been implicated in regulation of keratinocyte proliferation, differentiation, and apoptosis. As a result, it has been suggested as a drug target for a variety of dermatological conditions and itch. It has therefore been suggested that inhibition of TRPV3 by specific antagonists can address the above-mentioned conditions.KM-001, developed by Kamari Pharma, is a potent and selective TRPV3 antagonist. Kamari has demonstrated that KM-001 reduces Ca+2flux in keratinocytes and decreases cell proliferation accompanied by normalization of keratinocyte differentiation markers. Efficacy was demonstrated in in vivo studies, using the DS-Nh mice model, where it was able to normalize epidermal hyperkeratosis. In addition, the compound significantly reduced pruritus which is characteristic of this model and of many types of PPK. KM-001 topical formulation demonstrates favorable safety profile in rodents and minipigs and significant efficacy in animal models.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 19
• Est. completion date: August 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Read, understood, and signed an informed consent form (ICF) before any investigational procedure(s) are performed.

2. Male and female and aged 18 - 75 years (inclusive) at the time of screening.

3. Clinical diagnosis of:

• Punctate palmoplantar keratoderma type I disease with confirmed heterozygous mutation in AAGAB gene. OR
• PC with confirmed heterozygous mutation in either KRT16, KRT17, KRT6A, KRT6B or KRT6C mutations.

4. The target treatment region is 0.5% to 4% BSA including target lesion.

5. CGI-S score (as assessed by the CI at the screening visit) of =2.

6. Female patients of childbearing potential1 must use a highly effective birth control method2 (failure rate ?1% per year when used consistently and correctly) (28) throughout the trial and for at least 4 weeks after last application of IMP. In addition to the hormonal contraception, female patients must agree to use a supplemental barrier method during intercourse with a male partner (i.e., male condom) throughout the trial and for at least 4 weeks after last application of IMP. Female patients must be having regular menstrual periods (interval of 21 to 35 days, duration of 2 to 7 days for several months) at the baseline visit (as reported by the patient); exception: patients using hormonal contraceptives that preclude regular menstrual periods, menopausal or hysterectomised patients. A male patient with a pregnant or non-pregnant female partner of childbearing potential1 must use adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice; as a minimum, the male patient must agree to use condom during treatment and until the end of relevant systemic exposure in the male patient (7 days post-treatment).

1. A female patient is considered of childbearing potential, i.e., fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for at least 12 months without an alternative medical cause prior to screening (28).

2. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) or progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) 28 days prior to screening, bilateral tubal occlusion, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomised/permanently sterile by bilateral orchidectomy partner (given that the partner is the sole sexual partner and has received medical assessment of the surgical success), or sexual abstinence (refraining from heterosexual intercourse during the entire trial/treatment period of risk associated with the IMPs) (28). This period of contraception should be extended for at least 4 weeks after last application of IMP.

7. Female patients must refrain from donating eggs throughout the trial and for 4 weeks after the last IMP administration. Male patients must refrain from sperm donation throughout the trial and for 7 days after the last IMP administration.

8. Female patients of non-childbearing potential must meet 1 of the following criteria:

1. Absence of menstrual bleeding for 1 year prior to screening without any other medical reason.

2. Documented hysterectomy or bilateral oophorectomy at least 3 months before the trial.

9. Patient is willing and able to comply with all the time commitments and procedural requirements of the protocol.

Exclusion Criteria:

1. History of drug or alcohol abuse in the past 2 years.

2. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).

3. Positive hepatitis B surface antigen [HbsAg], hepatitis B core antibody [HbcAb], hepatitis C antibody, or human immunodeficiency virus (HIV) antibody serology results at the screening visit.

4. Known hypersensitivity or any suspected cross-allergy to the API and/or excipients.

5. Any medical or active psychological condition or any clinically relevant laboratory abnormalities, such as, but not limited, to elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (>3 × upper limit of normal [ULN]) in combination with elevated bilirubin (>2 × ULN), at the screening/baseline visit.

6. Planned or expected major surgical procedure during the clinical trial.

7. Patient is unwilling to refrain from using prohibited medications during the clinical trial.

8. Currently participating or participated in any other clinical trial of an IMP or device, within the past 4 months before the screening visit.

9. Cutaneous infection or another underlying condition of the skin which may impact the assessments or trial participation.

10. Cutaneous infection of the area to be treated with IMP within 2 weeks before the screening visit or any infection of treatment area requiring treatment with oral, parenteral antibiotics, antivirals, antiparasitics or antifungals or any topical within 2 weeks before the screening visit.

11. Pregnant or breastfeeding patient.

12. Failure to satisfy the investigator of fitness to participate for any other reason.

13. Having received any of the prohibited treatments in Table 5 within the specified timeframe before the baseline visit. -

Related Conditions & MeSH terms

• Pachyonychia Congenita

Intervention

Drug:
• KM-001 cream 1% 12 weeks treatment.
KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.

Diagnostic Test:
• Physical Examination
A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort): The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease. Symptom-directed physical examinations will be performed at all other trial visits. Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination.
• Vital Signs
Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
• Serum chemistry
Approx. 5 mL whole blood will be collected after an =8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
• Hematology
Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute [abs.]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
• Serology
Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
• Urinalysis
General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
• ECG test
A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
• Pharmacokinetics Assessments
Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit. Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable. Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2.
• Clinical global impression of severity (CGI-S)
Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= "none" to 4= "very severe") modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort). The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. "Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
• Visual Analogue Scale (VAS) pain scale
The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit. The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort). The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question: "How was your worst pain intensity in the past 24 hours?"
• Peak pruritus-numerical rating scale (PP-NRS)
The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit. The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort). The PP-NRS was designed to measure peak pruritus, or "worst" itch, over the previous 24 hours based on the following question: "On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
• Patient global impression of change (PGI-C) scoring
The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort. The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows: Since the start of the trial, my overall status has: from, 1= "very much improved" to 7= "very much worse"
• Patient global impression of severity (PGI-S) scoring
The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort. The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows: Please rate the severity of your disease right now, from 1= "none" to 5= "very severe"
• Lesion photography
High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort. The photographs will be taken under standardised conditions, using imitoMeasure (? imito AG 2016-2022).

Drug:
• KM-001 cream 1% 16 weeks treatment.
KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.

Locations

Country	Name	City	State
United Kingdom	Royal London Hospital-Clinical Research Facility-11D (11th Floor) Whitechapel, London, E1 1FR,	London	Whitechapel Rd

Sponsors (1)

Lead Sponsor	Collaborator
Kamari Pharma Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory end point- will be assessed by characterize the time to reach Maximum plasma concentration (tmax) of KM-001	KM-001 plasma levels will be collected at screening (Day -7 to -1, any time during the visit), on Days 7 and 84 (EoT) 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28 and 42: 1 sample after the first dose, before the second dose, as late as possible in the visit, on Day 112 and at ET visit: at any time during the visit. The time to reach Maximum plasma concentration (tmax) will be determined.	Up to 112 days
Other	Exploratory end point- will be assessed by characterize the Area under the plasma concentration versus time curve (AUC) of KM-001	KM-001 plasma levels will be collected at screening (Day -7 to -1, any time during the visit), on Days 7 and 84 (EoT) 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28 and 42: 1 sample after the first dose, before the second dose, as late as possible in the visit, on Day 112 and at ET visit: at any time during the visit. The Area under the plasma concentration versus time curve (AUC) will be determined.	Up to 112 days
Other	Exploratory end point -will be assess the efficacy of KM-001 1% in pain reduction resulted by Visual analogue scale (VAS) questionnaire.	Mean change from baseline (Day 1 [Visit 2] to Day 84 [Visit 10, EoT]) in pain assessed by VAS score (0= "no pain" to 100= "severe intolerable pain").	Up to 84 days
Other	Exploratory end point -will be assess the efficacy of KM-001 1% in itch reduction resulted by Peak pruritus-numerical rating scale (PP-NRS) questionnaire.	Itch assessment using the PP-NRS (0= "no itch" to 10= "worst imaginable itch")	Up to 84 days
Other	Exploratory end point -will be assess the change in the external characteristics of the callus surface using photography and "imitoMeasur" software.	The Changes in the treated callus morphology (Referring to the following parameters: fissuring, neurovascular structures, and erythema around the calluses) will be assessed (decreasing / increasing) using lesions photography. The treated lesions will be photographed using "imitoMeasur" software on Days 1, 7, 28, 42, 63, 84, and 112.	Up to 112 days
Primary	Safety endpoint will be assessed through collection and analysis of adverse events.	Incidence rate of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) grouped by body system up to the patient´s end of trial (Day 112 [Visit 12]) or early termination [ET] visit]).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of Hematology- laboratory blood test profile.	Safety will be assessed by the % of change from normal range in clinical Hematology blood test profile from baseline (Day 1) up to day 112.; Data management team will assess and review the laboratory blood test results (Hematology). Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: WBC (K/µl) and platelet count (K/µl), neutrophils (absolute [abs.])(K/µl), lymphocytes (abs.)(K/µl), monocytes (abs.) (K/µl), eosinophiles (abs.)(K/µl) and basophiles (abs.) (K/µl) and reticulocyte count (K/µl).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of MCH result in laboratory blood test.	Safety will be assessed by the % of change from normal range in MCH (pg) blood test result, from baseline (Day 1) up to day 112.; Data management team will assess and review the MCH lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of MCV result in laboratory blood test.	Safety will be assessed by the % of change from normal range in MCV(fl) laboratory blood test result, from baseline (Day 1) up to day 112.; Data management team will assess and review the MCV lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of haematocrit result in laboratory blood test.	Safety will be assessed by the % of change from normal range in haematocrit (%) laboratory blood test result, from baseline (Day 1) up to day 112.; Data management team will assess and review the haematocrit lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of hemoglobin result in laboratory blood test.	Safety will be assessed by the % of change from normal range in hemoglobin (g/dL) laboratory blood test result, from baseline (Day 1) up to day 112.; Data management team will assess and review the hemoglobin lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of RBC result in laboratory blood test.	Safety will be assessed by the % of change from normal range in RBC (M/µl) laboratory blood test result, from baseline (Day 1) up to day 112.; Data management team will assess and review the RBC lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of Sodium, potassium and chloride results in chemistry laboratory blood test.	Safety will be assessed by the % of change from normal range in chemistry laboratory blood test profile, from baseline (Day 1) up to day 112.; Data management team will assess and review the chemistry lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: Sodium (mmol/L), potassium (mmol/L) and chloride (mmol/L).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of: Glucose fasting , BUN/Ur, creatinine, bilirubin total and direct, calcium, uric acid, and bilirubin result, in chemistry laboratory blood test.	Safety will be assessed by the % of change from normal range in chemistry laboratory blood test profile, from baseline (Day 1) up to day 112.; Data management team will assess and review the chemistry lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: Glucose fasting (mg/dL), BUN/Ur (mg/dL), creatinine (mg/dL), bilirubin total (mg/dL) and direct (mg/dL), calcium (mg/dL), uric acid (mg/dL), and bilirubin (mg/dL).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of Alkaline phosphatase, AST, ALT and GGT result in chemistry- laboratory blood test.	Safety will be assessed by the % of change from normal range in chemistry laboratory blood test profile, from baseline (Day 1) up to day 112.; Data management team will assess and review the chemistry lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: Alkaline phosphatase (U/L), AST (U/L), ALT (U/L) and GGT (U/L).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of Albumin and total protein result in chemistry- laboratory blood test.	Safety will be assessed by the % of change from normal range in chemistry blood test profile, from baseline (Day 1) up to day 112.; Data management team will assess and review the chemistry lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: Albumin (g/dL) and total protein (g/dL).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of Serology -in laboratory blood test profile.	Safety will be assessed by the % of change from normal range in serology clinical blood test profile, from baseline (Day 1) up to Day 112.; Data management team will assess and review the serology lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: HBsAg (positive/negative), HBcAb (positive/negative), hepatitis C antibody (positive/negative), or HIV antibody (positive/negative).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of urine laboratory profile.	Safety will be assessed by the % of change in clinical urine laboratory profile from baseline (Day 1) up to Day 112.; Data management team will assess and review the urine lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; the following values will be assessed: Glucose (mg/dl), protein (mg/ml),urobilinogen (mg/ml) and ketones (mg/ml).	Up to 112 days
Primary	Safety endpoint-will be assessed by the % of change from normal range in the collection of Specific gravity , pH, blood and nitrites result in urine laboratory profile.	Safety will be assessed by the % of change in clinical urine laboratory profile from baseline (Day 1) up to Day 112.; Data management team will assess and review the urine lab test results. Exceptional values above the norm or below the norm indicate an aggravation of the participant's condition.; The following values will be assessed: Specific gravity , pH, blood and nitrites.	Up to 112 days
Primary	Safety endpoint-Mean change in body temperature measurement from baseline.	Mean changes in body temperature from baseline (Day 1) up to Day 112.	Up to 112 days
Primary	Safety endpoint-Mean change in pulse measurement from baseline.	Mean changes in pulse (unites: beats per minute) measurements from baseline (Day 1)up to Day 112.	Up to 112 days
Primary	Safety endpoint- Mean change in blood pressure measurement from baseline.	Mean changes in blood pressure (systolic and diastolic blood pressure [unites: mm Hg]) measurements from baseline (Day 1) up to Day 112.	Up to 112 days
Primary	Safety endpoint-ECG	Mean changes in ECG parameters from baseline (Day 1) up to Day 112. the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTC interval and QRS complex.	Up to 112 days
Secondary	Efficacy end point - will be assessed by Clinical global impression of severity (CGI-S) questionaries	Percent responders in CGI-S scale (0= "none" to 4= "very severe") on Day 84 [Visit 10, EoT] compared to baseline (Day 1); a responder is defined to have an improvement of at least 2 points in disease severity on Day 84 [Visit 10, EoT] compared to baseline (Day 1).	Up to 84 days
Secondary	Efficacy end point - will be assessed by Patient global impression of change (PGI-S) questionaries	Mean change from baseline (Day 1 [Visit 2] to Day 84 [Visit 10, EoT]) in PGI-S. scale: 1= "none" 5="very severe"	Up to 84 days
Secondary	Efficacy end point - will be assessed by Patient global impression of change (PGI-C) questionaries	Mean change from baseline (Day 1 [Visit 2] to Day 84 [Visit 10, EoT]) in PGI-C. scale: 1="very much improved" 7="very much worse"	Up to 84 days